Seeking Alpha

Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox...

Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox liver-cancer treatment with China's Hisun, which will pay $5M upfront and manufacture the drug. The deal is a precursor to a China licensing agreement that could be worth hundreds of millions of dollars to Celsion, and comes ahead of the results of Phase III trials for ThermoDox. (PR)
Comments (5)
  • buyitcheap
    , contributor
    Comments (1848) | Send Message
     
    Wow. Hisun's pretty early on this.... they must have something on the Phase 3's to be that confident to put down that kind of call option.
    22 Jan 2013, 09:06 AM Reply Like
  • PeakOiler
    , contributor
    Comments (293) | Send Message
     
    Yeah, right. This is peanuts and a weak attempt by management to generate some positive PR. Only the data knows.
    22 Jan 2013, 09:15 AM Reply Like
  • buyitcheap
    , contributor
    Comments (1848) | Send Message
     
    Exactly.
    22 Jan 2013, 09:19 AM Reply Like
  • jimmy J
    , contributor
    Comments (62) | Send Message
     
    There is no reason to think the data will not be positive as the research results to date have continually supported each phase , this agreement . Hisun will make the product and it will be used worldwide.
    22 Jan 2013, 09:53 AM Reply Like
  • begs
    , contributor
    Comments (7) | Send Message
     
    Agree, sounds a lot like hype
    22 Jan 2013, 10:40 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|